RADX

Radiopharm Theranostics Limited Depositary Receipt (RADX) | Rumor.io

Radiopharm Theranostics

RADX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,443

Bullish sentiment (50-day avg)55%

Price to earnings ratio-0.29

Market capitalization22.2M

Earnings per share-3.76

Dividend yield (TTM)—

Revenue (annual)3.6M

Net income (annual)-38.3M

Social

What share of all stock conversation is about RADX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 28

The volume for $RADX has been significantly high, with over 136k shares traded, and some users are speculating about the reason behind it.
There is a possibility of a bullish engulfing candlestick pattern on the daily chart if the price closes above $2.50, which could mark the end of a bearish exhaustion cycle and lay a healthier foundation for September.
The company's leadership has been criticized for its handling of a recent financing/raising capital situation, but some users are optimistic that it may be due to complications with the Lantheus acquisition and the uncertainty surrounding licensing/partnership deals.

Generated by AI

Sentiment

Of the messages about RADX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	66.67% +6.67	39.13% -21.21	73.05% -7.18
Bearish	—	33.33% -6.67	60.87% +21.21	26.95% +7.18

Bullish· Jul 24

Radiopharm Theranostics Limited's recent raise has been successful in advancing its clinical pipeline and launching the RAD101 registrational study, which could lead to significant growth in the company's value.
The company's assets, particularly RAD101, have been attracting major buyers, including Curium, Telix, and Lantheus, which could lead to a strategic asset sale and a substantial upfront payment.
The standalone value of RAD204 is estimated to be between $75-500 million, with the potential to reach $1 billion if it demonstrates strong efficacy in a registrational path, making it a potentially lucrative investment opportunity.

Bearish· Jul 24

The management of Radiopharm Theranostics Limited (RADX) is perceived as incompetent, leading to a significant decline in the stock's value.
The company's decision to halt trading and raise funds through a registered direct offering is seen as a predatory and despicable move, treating short-sellers better than loyal investors.
The valuation of RADX is considered absurd, with the stock being worth less than cash, and the company's management is accused of being clueless about stock psychology, leading to a self-inflicted decline in the stock's price.

Generated by AI

Topics

Of the messages about RADX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	92.31%	56.81%
Technical Analysis	—	0%	7.69%	34.17%
Analysts	—	0%	0%	5.5%
Controversies	—	0%	0%	0.32%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	3.2%

Announcements· Jul 22

Radiopharm Theranostics announces positive Phase 2b trial results for RAD101, showing 93% concordance with MRI in 30 patients and supporting Phase 3 in 4Q26.
The company reports encouraging Phase 1 results for RAD204, with a confirmed durable partial RECIST response, no dose-limiting toxicities, and tumor reduction in advanced solid tumor patients.
Radiopharm Theranostics launches a material capital raising reportedly worth $16 million, following good news with two separate cancer treatments, RAD101 and RAD204.

Technical Analysis· Dec 16

$RADX has strong support around $6 levels, with a possible bounce and drift up.
Breaking $7 could lead to a run to $8.50, while a failure to get back above $7 may be a sign to exit.
The stock is in a descending wedge, with a possible buy zone around $5.9-$6.1, but with a tight stop loss due to the risk of no guarantees.

Generated by AI

Community

Of the messages about RADX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	68.92%	47.46%
Newcomers	0%	0%	31.08%	52.54%

Regulars· Aug 20

The company is advancing its RAD202 Phase 1 trial to the next dose level of 180mCi in patients with HER2+ advanced solid tumors, with previous diagnostic study results showing strong tumor uptake at 130mCi.
The RAD204 trial has shown strong activity, with one patient achieving a confirmed PR and remaining progression-free for over 7 months, and the second patient showing 7% shrinkage after the first treatment.
The company's RAD101 asset is expected to be sold for anywhere from $100-250 million, and RAD204 has just started to produce real efficacy, with the potential to reach $500 million+.

Newcomers· Jul 24

Radiopharm Theranostics Limited has announced a dilutive raise of $4.1M through a registered direct offering of 1.28M ADSs at $3.16/ADS, with concurrent warrants exercisable at $3.79/ADS expiring in July 2029.
The company's share price has fallen 45.7% since filing, with investors questioning the decision to raise capital through a dilutive offering, citing concerns over management's ability to manage stock psychology.
The halt on trading has been lifted, and the stock price has risen by 11.29% since the first alert, with some investors taking a long-term hold despite the dilutive raise.

Generated by AI

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint Meeting with FDA planned on October 1st to align on RAD101Phase 3 pivotal trial protocol Brain Metastases Imaging has ~$600 million total addressable market, and there are no currently approved PET products SYDNEY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on

16d agoYahoo Finance

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting potential of RAD301 and continuation of its clinical development SYDNEY, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceutical

21d agoYahoo! Finance Canada

Radiopharm doses first patient in second cohort of RV-01 trial

1mo agoInvesting.com

Radiopharm advances RAD202 trial to higher dose level

1mo agoInvesting.com

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical proof-of-concept with positive safety and biodistribution SYDNEY, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for ar

1mo agoYahoo! Finance Canada

Radiopharm schedules FDA meeting for brain imaging agent RAD101

1mo agoInvesting.com

Also Discussed

Investors talking about RADX also mention

#	Name	Attention
1	Lantheus Holdings Inc.LNTH	0%0
2	Telix Pharmaceuticals Limited American Depositary SharesTLX	0%new
3	Polyrizon Ltd.PLRZ	0%0
4	Decent Holding Inc. Class A Ordinary SharesDXST	0.03%new
5	AMC Robotics CorporationAMCI	0%0
6	Locafy LimitedLCFY	0%new
7	SMX (Security Matters) Public Limited CompanySMX	0%+0
8	Intelligent Bio Solutions Inc.INBS	0%0
9	Monopar Therapeutics Inc.MNPR	0%0
10	A SPAC III Acquisition Corp. Class A Ordinary SharesASPC	0%0

Radiopharm Theranostics Limited Depositary Receipt

Healthcare
Biotechnology

Radiopharm Theranostics Limited Depositary Receipt is the U.S.-traded depositary receipt for Radiopharm Theranostics Limited, a clinical-stage biopharmaceutical company focused on radiopharmaceutical products for diagnostic imaging and targeted therapy. The company develops oncology-focused technologies designed to address areas of high unmet medical need, with programs spanning both pre-clinical and clinical stages of development. Its current pipeline includes diagnostic and therapeutic candidates built around radiopharmaceutical platforms for cancer targeting, reflecting a business centered on precision medicine and molecular imaging. Radiopharm Theranostics Limited serves researchers, clinicians, and healthcare stakeholders working in cancer diagnosis and treatment, and its depositary receipt provides a market-facing representation of the company’s ordinary shares for international investors.

Website

Location

62 Lygon Street

Carlton, VIC, 3053

Australia

Social

What share of all stock conversation is about RADX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 28

The volume for $RADX has been significantly high, with over 136k shares traded, and some users are speculating about the reason behind it.
There is a possibility of a bullish engulfing candlestick pattern on the daily chart if the price closes above $2.50, which could mark the end of a bearish exhaustion cycle and lay a healthier foundation for September.
The company's leadership has been criticized for its handling of a recent financing/raising capital situation, but some users are optimistic that it may be due to complications with the Lantheus acquisition and the uncertainty surrounding licensing/partnership deals.

Generated by AI

Sentiment

Of the messages about RADX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	66.67% +6.67	39.13% -21.21	73.05% -7.18
Bearish	—	33.33% -6.67	60.87% +21.21	26.95% +7.18

Bullish· Jul 24

Radiopharm Theranostics Limited's recent raise has been successful in advancing its clinical pipeline and launching the RAD101 registrational study, which could lead to significant growth in the company's value.
The company's assets, particularly RAD101, have been attracting major buyers, including Curium, Telix, and Lantheus, which could lead to a strategic asset sale and a substantial upfront payment.
The standalone value of RAD204 is estimated to be between $75-500 million, with the potential to reach $1 billion if it demonstrates strong efficacy in a registrational path, making it a potentially lucrative investment opportunity.

Bearish· Jul 24

The management of Radiopharm Theranostics Limited (RADX) is perceived as incompetent, leading to a significant decline in the stock's value.
The company's decision to halt trading and raise funds through a registered direct offering is seen as a predatory and despicable move, treating short-sellers better than loyal investors.
The valuation of RADX is considered absurd, with the stock being worth less than cash, and the company's management is accused of being clueless about stock psychology, leading to a self-inflicted decline in the stock's price.

Generated by AI

Topics

Of the messages about RADX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	92.31%	56.81%
Technical Analysis	—	0%	7.69%	34.17%
Analysts	—	0%	0%	5.5%
Controversies	—	0%	0%	0.32%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	3.2%

Announcements· Jul 22

Radiopharm Theranostics announces positive Phase 2b trial results for RAD101, showing 93% concordance with MRI in 30 patients and supporting Phase 3 in 4Q26.
The company reports encouraging Phase 1 results for RAD204, with a confirmed durable partial RECIST response, no dose-limiting toxicities, and tumor reduction in advanced solid tumor patients.
Radiopharm Theranostics launches a material capital raising reportedly worth $16 million, following good news with two separate cancer treatments, RAD101 and RAD204.

Technical Analysis· Dec 16

$RADX has strong support around $6 levels, with a possible bounce and drift up.
Breaking $7 could lead to a run to $8.50, while a failure to get back above $7 may be a sign to exit.
The stock is in a descending wedge, with a possible buy zone around $5.9-$6.1, but with a tight stop loss due to the risk of no guarantees.

Generated by AI

Community

Of the messages about RADX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	68.92%	47.46%
Newcomers	0%	0%	31.08%	52.54%

Regulars· Aug 20

The company is advancing its RAD202 Phase 1 trial to the next dose level of 180mCi in patients with HER2+ advanced solid tumors, with previous diagnostic study results showing strong tumor uptake at 130mCi.
The RAD204 trial has shown strong activity, with one patient achieving a confirmed PR and remaining progression-free for over 7 months, and the second patient showing 7% shrinkage after the first treatment.
The company's RAD101 asset is expected to be sold for anywhere from $100-250 million, and RAD204 has just started to produce real efficacy, with the potential to reach $500 million+.

Newcomers· Jul 24

Radiopharm Theranostics Limited has announced a dilutive raise of $4.1M through a registered direct offering of 1.28M ADSs at $3.16/ADS, with concurrent warrants exercisable at $3.79/ADS expiring in July 2029.
The company's share price has fallen 45.7% since filing, with investors questioning the decision to raise capital through a dilutive offering, citing concerns over management's ability to manage stock psychology.
The halt on trading has been lifted, and the stock price has risen by 11.29% since the first alert, with some investors taking a long-term hold despite the dilutive raise.

Generated by AI

Radiopharm Theranostics

Social

Aug 28

Bullish· Jul 24

Bearish· Jul 24

Announcements· Jul 22

Technical Analysis· Dec 16

Regulars· Aug 20

Newcomers· Jul 24

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

Radiopharm doses first patient in second cohort of RV-01 trial

Radiopharm advances RAD202 trial to higher dose level

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Radiopharm schedules FDA meeting for brain imaging agent RAD101

Also Discussed

Radiopharm Theranostics Limited Depositary Receipt

Company Information

Location

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

Radiopharm doses first patient in second cohort of RV-01 trial

Radiopharm advances RAD202 trial to higher dose level

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Radiopharm schedules FDA meeting for brain imaging agent RAD101

Also Discussed

Social

Aug 28

Bullish· Jul 24

Bearish· Jul 24

Announcements· Jul 22

Technical Analysis· Dec 16

Regulars· Aug 20

Newcomers· Jul 24